{
  "nctId": "NCT02132676",
  "briefTitle": "Shared Health Appointments and Reciprocal Enhanced Support",
  "officialTitle": "Peer Support to Enhance Diabetes Shared Medical Appointments: Examining Comparative Effectiveness in VA Health Systems",
  "protocolDocument": {
    "nctId": "NCT02132676",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2020-06-19",
    "uploadDate": "2020-06-19T14:47",
    "size": 280840,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02132676/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 1536,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2016-04-25",
    "completionDate": "2019-07-30",
    "primaryCompletionDate": "2019-06-28",
    "firstSubmitDate": "2013-08-21",
    "firstPostDate": "2014-05-07"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\nVeterans enrolled into diabetes Shared Medical Appointments (SMAs) at participating sites, and a random subset of those meeting criteria for diabetes SMAs who have not yet participated:\n\n* Veteran receiving care at a participating VA Medical Center\n* Meets at least one of the following criteria in the past 2 years;\n\n  * at least 1 VA hospitalization with a diabetes-related International Classification Of Diseases-9 (ICD-9) code,\n  * at least 2 VA outpatient visits with a diabetes-related ICD-9 code, or\n  * At least 1 VA prescription for a glucose control medication (insulin or oral agent) or monitoring supplies\n* Poor glycemic control, indicated by a HbA1c in the past 6 months or:\n\n  * at least 7.5% if age \\<70, or\n  * at least 8% if age 70+\n* Has a current address and telephone number listed in VA databases\n* Is competent to provide informed consent\n* Can communicate in English and by telephone\n* Able to participate in an outpatient program\n\nExclusion Criteria:\n\nFor no intervention control group:\n\n* Active substance abuse disorder (smoking cigarettes is not an exclusion)\n* Serious psychiatric illness (bipolar disorder, dementia, schizophrenia, or personality disorders)\n* Terminally ill\n* Prisoner",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change in Glycemic Control",
        "description": "Glycemic control (measured by Hemoglobin A1c) in each group will be assessed by the comparison of an average of the values obtained during routine outpatient clinical practice in 6-month windows preceding baseline and following the 6 and 12-month post-enrollment evaluation periods. In addition to measuring absolute values of A1c, the investigators will also examine the change in the percentage of patients with an average A1c \\> 8%.",
        "timeFrame": "6 months and 12 months post-enrollment"
      }
    ],
    "secondary": [
      {
        "measure": "Change in Systolic Blood Pressure (SBP)",
        "description": "Systolic blood pressure (SBP) in each group will be assessed by the comparison of an average of the values obtained during routine outpatient clinical practice in 6-month windows preceding baseline and following the 6 and 12-month post-enrollment evaluation periods. In addition to measuring absolute values, the investigators will also examine the change in percentage of patients with an average SBP \\> 140.",
        "timeFrame": "6 months and 12 months post-enrollment"
      },
      {
        "measure": "Insulin Starts",
        "description": "The number of participants who are not on insulin at baseline and are started on insulin during the 6 and 12-month post-enrollment periods will be totaled and compared for the SMA group and the no intervention control group. For the no intervention control group, baseline will be the date they are identified by the data manager. For the SMA group, baseline will be the date of the first SMA.",
        "timeFrame": "6 months and 12 months post-enrollment"
      },
      {
        "measure": "Emergency Department (ED) Visits",
        "description": "Major utilization events (admissions, bed days of care, and outpatient visits) will be collected from electronic medical records. Outpatient visits will be limited to those clinics most likely to be impacted by the intervention (e.g., primary care visits, diabetes specialty visits, and nurse visits).",
        "timeFrame": "6 months and 12 months post-enrollment"
      },
      {
        "measure": "Statin Starts",
        "description": "The number of participants who are not on a statin at baseline and are started on insulin during the 6 and 12-month post-enrollment periods will be totaled and compared for the SMA group and the no intervention control group. For the no intervention control group, baseline will be the date they are identified by the data manager. For the SMA group, baseline will be the date of the first SMA.",
        "timeFrame": "6 months and 12 months post-enrollment"
      },
      {
        "measure": "Change in Number of Classes of Anti-hypertensive Meds",
        "description": "Change in antihypertensive use (number of classes of prescribed anti-hypertensives) in each group will be assessed at baseline and following the 6 and 12-month post-enrollment evaluation periods. For the no intervention control group, baseline will be the date they are identified by the data manager. For the SMA group, baseline will be the date of the first SMA.",
        "timeFrame": "6 months and 12 months post-enrollment"
      },
      {
        "measure": "Change in Patient-reported Satisfaction With VA Care",
        "description": "Patients' satisfaction with VA care will be assessed through surveys at baseline and 6 and 12 months post-enrollment for the SMA group. The following relates to the scale used:\n\nScale name: VA Healthcare Satisfaction Scale Scale ranges: 1-6 (Strongly Disagree=1, Disagree=2, Slightly Disagree=3, Slightly Agree=4, Agree=5, Strongly Agree=6) Direction of range: Higher score indicates a better outcome",
        "timeFrame": "6 months and 12 months post-enrollment"
      },
      {
        "measure": "Change in Patient-reported Diabetes Distress",
        "description": "Patients' level of diabetes distress will be assessed through surveys at baseline and 6 and 12 months post-enrollment for the SMA group. The following relates to the scale used:\n\nScale name: Diabetes Distress Scale Scale ranges: 1-5 (Not a Problem=1, Minor Problem=2, Moderate Problem=3, Somewhat Serious Problem=4, Serious Problem=5) Direction of range: Lower score indicates a better outcome",
        "timeFrame": "6 months and 12 months post-enrollment"
      },
      {
        "measure": "Change in Patient-reported Degree of Diabetes Support",
        "description": "Patients' degree of diabetes support will be assessed through surveys at baseline and 6 and 12 months post-enrollment for the SMA group. The following relates to the scale used:\n\nScale name: Diabetes Support Scale Scale ranges: 1-6 (Strongly Disagree=1, Disagree=2, Slightly Disagree=3, Slightly Agree=4, Agree=5, Strongly Agree=6) Direction of range: Higher score indicates a better outcome",
        "timeFrame": "6 months and 12 months post-enrollment"
      },
      {
        "measure": "Change in Patient-reported Degree of Self-Efficacy",
        "description": "Patients' degree of self-efficacy will be assessed through surveys at baseline and 6 and 12 months post-enrollment for the SMA group. The following relates to the scale used:\n\nScale name: Williams Self-Efficacy Scale Scale ranges: 1-6 (Strongly Disagree=1, Disagree=2, Slightly Disagree=3, Slightly Agree=4, Agree=5, Strongly Agree=6) Direction of range: Higher score indicates a better outcome",
        "timeFrame": "6 months and 12 months post-enrollment"
      },
      {
        "measure": "Hospitalizations",
        "description": "Major utilization events (admissions, bed days of care, and outpatient visits) will be collected from electronic medical records. Outpatient visits will be limited to those clinics most likely to be impacted by the intervention (e.g., primary care visits, diabetes specialty visits, and nurse visits).",
        "timeFrame": "6 months and 12 months post-enrollment"
      },
      {
        "measure": "Length of Hospitalizations",
        "description": "Major utilization events (admissions, bed days of care, and outpatient visits) will be collected from electronic medical records. Outpatient visits will be limited to those clinics most likely to be impacted by the intervention (e.g., primary care visits, diabetes specialty visits, and nurse visits).",
        "timeFrame": "6 months and 12 months post-enrollment"
      },
      {
        "measure": "PCP Visits",
        "description": "Major utilization events (admissions, bed days of care, and outpatient visits) will be collected from electronic medical records. Outpatient visits will be limited to those clinics most likely to be impacted by the intervention (e.g., primary care visits, diabetes specialty visits, and nurse visits).",
        "timeFrame": "6 months and 12 months post-enrollment"
      },
      {
        "measure": "Nurse Case Manager Visits",
        "description": "Major utilization events (admissions, bed days of care, and outpatient visits) will be collected from electronic medical records. Outpatient visits will be limited to those clinics most likely to be impacted by the intervention (e.g., primary care visits, diabetes specialty visits, and nurse visits).",
        "timeFrame": "6 months and 12 months post-enrollment"
      },
      {
        "measure": "Endocrinology Visits",
        "description": "Major utilization events (admissions, bed days of care, and outpatient visits) will be collected from electronic medical records. Outpatient visits will be limited to those clinics most likely to be impacted by the intervention (e.g., primary care visits, diabetes specialty visits, and nurse visits).",
        "timeFrame": "6 months and 12 months post-enrollment"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 14,
      "otherCount": 0,
      "totalCount": 15
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 99,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:07.563Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}